Texas Compounding Pharmacy Sued After Recalled Glutathione Hospitalizes Patient
A lawsuit highlights the liability risks of sourcing IV wellness ingredients from compounding pharmacies.
A Texas woman filed a lawsuit on August 14, 2026, against Victory Medical Center Pharmacy after being hospitalized from a recalled lot of compounded glutathione, highlighting the severe liability risks medical directors face when outsourcing wellness formulations. The plaintiff, Amber DeeAnn Knowles, received an IV infusion of compounded Glutathione 200 mg/mL at a Texas wellness clinic on June 17, 2026. Within minutes of administration, she developed acute symptoms that required emergency ambulance transport and a subsequent hospitalization lasting until June 21, 2026. The lawsuit, filed in Travis County, Texas, by the Law Offices of John David Hart, asserts claims of negligence, products liability, and gross negligence.
The legal action links Knowles's injuries directly to a product safety failure. On August 5, 2026, Victory Medical Center Pharmacy recalled several lots of its multi-dose glutathione vials (specifically lots 1981940, 1980571, and 1984345) after FDA-posted testing revealed elevated bacterial endotoxin levels.
For aesthetic practice owners offering wellness infusions, this litigation underscores the critical importance of supply chain oversight. While the compounding pharmacy is the named defendant, the administering clinic is invariably caught in the fallout of a contaminated batch. To mitigate this risk, medical directors must establish rigorous quality-control protocols. This includes verifying that compounding partners perform batch-specific endotoxin testing, maintaining precise patient-to-lot logbooks for rapid tracing, and immediately auditing current stock to ensure no vials from recalled lots remain in clinical inventory.
Source: Morningstar / PR Newswire, https://www.morningstar.com/news/pr-newswire/20260814la04681/the-law-offices-of-john-david-hart-texas-woman-sues-victory-medical-center-pharmacy-an-austin-compounding-pharmacy-after-hospitalization-following-iv-infusion-from-recalled-lot